---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-053088"
form_type: "8-K"
ticker: "FEMY"
cik: "0001339005"
company_name: "FEMASYS INC"
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:16:53.705561+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Femasys Q3 net loss widens to $4.0M, revenue down 30%; FemaSeed gets FDA clearance

## Summary
- Net loss of $4.0M ($0.26/share) vs $3.0M ($0.25) in Q3 2022.
- Revenue $244K, down 30% from $347K; U.S. units down 18.4% YoY.
- Raised $11.3M via warrant exercises and ATM; cash $8.7M sufficient for >12 months.
- FDA 510(k) clearance for FemaSeed infertility treatment; FINALE trial for FemBloc enrolling.
- Gross margin improved to 64.7% from 62.2% on manufacturing efficiencies.

## SEC filing metadata
- accession: 0001140361-23-053088
- form_type: 8-K
- ticker: FEMY
- cik: 0001339005
- company_name: FEMASYS INC
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339005/000114036123053088/0001140361-23-053088-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339005/000114036123053088/ef2001466_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-053088
- JSON: https://secwatch.observer/filing/0001140361-23-053088.json
- Plain text: https://secwatch.observer/filing/0001140361-23-053088.txt

## Key facts
- Earnings Releases
  FEMASYS INC reported the third quarter ended September 30, 2023 results: revenue $244,361.
  - Period: the third quarter ended September 30, 2023
  - Revenue: $244,361
  - Result: reported results
  source text: 2022. The increase was largely due to increased compensation and professional costs, partially offset by decreased facility and overhead costs. • Sales decreased by $103,095 to $244,361 for the three months ended September 30, 2023 compared
  evidence_url: https://www.sec.gov/Archives/edgar/data/1339005/000114036123053088/0001140361-23-053088-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.